MedPath

A randomized controlled trial of the lumbar-type of HAL for the safety and efficacy in hemiplegic patients with acute stroke

Phase 2
Recruiting
Conditions
Cerebral infarction and cerebral hemorrhage patients with hemiplegia and sit-to-stand disorder
Cerebral infarction, Cerebral hemorrhage
Registration Number
JPRN-jRCTs032230039
Lead Sponsor
Matsumaru Yuji
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
44
Inclusion Criteria

1) Patients who can agree to the document by themselves. (However, if writing is difficult, set a writer)
2) Patients aged 16 years or older. (If you are under 18 years old, in addition to the signature of the person himself/herself, a signature by a parent or guardian is also needed)
3) Patients within 2 to 21 days after onset. (The day of stroke onset is treated as day 0)
4) Patients with Functional Ambulation Category (FAC) from 0 to 2.
5) Patients with FAC of 4 or more before onset.
6) Patients who can wear the lumbar-type of HAL. (Height is assumed to be 150 cm-190 cm, but the condition of use is not height, but for patients whose, body size such as thigh length, lower leg length, waist width, etc. fits)

Exclusion Criteria

1) Patients who have difficulty performing voluntary limb movements according to instructions due to consciousness disorder or cognitive decline.
2) Patients who have difficulty in training joint exercises or wearing lumbar-type of HAL due to complications such as heart disease and musculoskeletal system, which are problems during exercise.
3) Patients who cannot attach lumbar-type of HAL bio-electrode due to skin diseases.
4) Patients who participated in other interventional studies within 12 weeks of the start of this clinical study.
5) Patient who is judged to be medically unstable by the principal investigator or member doctors after comprehensively considering physical findings, examination findings, etc.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The amount of change from baseline to the end of the intervention in the Berg Balance Scale (BBS)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath